[1]
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110: 201-4.
[3]
Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 2016; 26: 43-51.
[4]
Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: A multicentric prospective study. Eur J Cancer Prev 2016; 26(4): 346-50.
[5]
Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta 2015; 446: 147-55.
[6]
American Institute of Ultrasound in Medicine. AIUM Practice Parameter for the performance of ultrasound of the female pelvis. Laurel (MD): AIUM;
2014. Available from:. http://www.aium.org/resources/guidelines/female Pelvis.pdf (Accessed on: October, 15 2018).
[7]
Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77: 454-9.
Call for Papers in Thematic Issues
31 December, 2025
RARE CASES IN GYNECOLOGY-OBSTETRICS
With the development of diagnostic and therapeutic techniques (such as ART techniques) and the immersion of new pathologies (such as COVID19), we are witnessing an increase in the incidence of pathologies that were previously described as rare or exceptional. the practitioner sometimes confronts difficult situations in these cases in diagnostic ...read more
Article Metrics
12
5